Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Theoret

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Advances in Hematology & Oncology : H&O|January 6, 2023
Talking to the FDA about dose optimization and the aims of Project OptimusMarc Theoret, Mirat Shah, Atiqur Rahman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall SurvivalMargret Merino, Yvette Kasamon, Marc Theoret, et al.
The Oncologist|August 19, 2022
FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaNajat Bouchkouj, Xue Lin, Xiaofei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Reply to H. McLeod et alChana Weinstock, Laura L Fernandes, Marc Theoret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Totality of the Evidence: Optimizing Dosage Selection Strategies in OncologyLaura A Levit, Mirat Shah, Mark J Ratain, et al.
The Oncologist|April 11, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular LymphomaNajat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, et al.
Pediatric Blood & Cancer|May 13, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaMargret Merino, Yvette Kasamon, Hongshan Li, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|May 9, 2025
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled AnalysisAsma Dilawari, Mori J Krantz, Ilynn Bulatao, et al.
Journal for Immunotherapy of Cancer|April 26, 2014
Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluationRamjay S Vatsan, Peter F Bross, Ke Liu, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Advances in Hematology & Oncology : H&O|January 6, 2023
Talking to the FDA about dose optimization and the aims of Project OptimusMarc Theoret, Mirat Shah, Atiqur Rahman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall SurvivalMargret Merino, Yvette Kasamon, Marc Theoret, et al.
The Oncologist|August 19, 2022
FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaNajat Bouchkouj, Xue Lin, Xiaofei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Reply to H. McLeod et alChana Weinstock, Laura L Fernandes, Marc Theoret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Totality of the Evidence: Optimizing Dosage Selection Strategies in OncologyLaura A Levit, Mirat Shah, Mark J Ratain, et al.
The Oncologist|April 11, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular LymphomaNajat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, et al.
Pediatric Blood & Cancer|May 13, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaMargret Merino, Yvette Kasamon, Hongshan Li, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|May 9, 2025
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled AnalysisAsma Dilawari, Mori J Krantz, Ilynn Bulatao, et al.
Journal for Immunotherapy of Cancer|April 26, 2014
Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluationRamjay S Vatsan, Peter F Bross, Ke Liu, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Pageof 2